ArticleAdvances in therapy2025
Insights from Patients and Physicians About Use of Evolocumab for LDL-C Management.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLow-density lipoprotein-cholesterol (LDL-C) is a causal modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), and evolocumab-a proprotein subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody-is effective in substantially decreasing LDL-C concentrations. However, many patients who might benefit from PCSK9 inhibitor treatment as per current guideline recommendations will not receive it. Our study aimed to assess patient and physician satisfaction with evolocumab, including perceptions of treatment experience and effectiveness.
methodsThe Treatment Satisfaction Questionnaire for Medication (TSQM)-9 (nine items; 7- or 5-point Likert scale responses) evaluated satisfaction in 130 adult patients (50% women) using evolocumab. A separate survey (five items; 5-point Likert scale responses) was developed to evaluate satisfaction in 130 physicians (50% primary care providers, 50% cardiologists) who prescribe evolocumab. Participants were recruited in the USA from pre-existing panels. Samples were stratified by US region (West, South, Northeast, and Midwest).
resultsOverall 96.1% of patients (mean age 53 years; 78% white) and 90.8% of physicians (mean age 50 years; 81% male; 63% white) were satisfied to various degrees with evolocumab. Patient reporting described various degrees of satisfaction with the ability of evolocumab to prevent or treat their condition (93.8%), relieve their symptoms (95.3%), and with the time it takes to start working (94.8%). They also found evolocumab convenient (92.3%) and easy to use (94.7%). Physicians were satisfied to various degrees with evolocumab's ability to control elevated LDL-C (93.1%) and the outcomes observed (94.6%) in their patients. They were also satisfied with evolocumab's convenience for patients (74.6%), their willingness to take it (79.2%), and its dosing frequency (85.4%).
conclusionsA large majority of patients and physicians reported high satisfaction levels about their experience with evolocumab treatment. This may help inform treatment decisions when choosing lipid-lowering therapy in patients with ASCVD and elevated LDL-C concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.